From 25 to 28 May, Moscow hosted the second All-Russia congress named
“Innovative technologies in endocrinology”, in which a number of CIS
countries were represented. Chairing the Scientific and Organisational
Committee was Veronika Skvortsova, Minister of Health of the Russian
Federation and Academician Ivan Dedov, President of the non-governmental
organisation named “The Russian Association of Endocrinologists”, and
Director of the federal state budgetary enterprise named “Endocrinology
Research Centre” attached to the Ministry of Health.
The All-Russia Congress “Innovative technologies in endocrinology” is a
prestigious medical forum held at the international level. This year,
it brought together over 1300 specialists in the field of endocrinology
and related professions from the Russian Federation, the CIS, Europe,
and the USA.
On the agenda of the Congress were symposiums, plenary lectures,
seminars, round tables, demonstrations of the latest information
technologies and research paper contests for young scientists, each of
which was a place for discussion of current issues in the key areas of
endocrinology. The main topics for discussion were as follows:
Epidemiology of endocrine diseases. The future of endocrinology –
preventive, predictive, personalized medicine in the XXI century. Genome
analysis – a new paradigm for solving medico-genetic problems.
Technologies for integrating achievements of molecular medicine into
clinical practice. Modern strategy of diagnostics, treatment, and
preventive care of diabetes and its complications. Innovative
achievements in diagnostics, treatment, and preventive care of
neuroendocrine diseases. Reproductive medicine: high technologies in
gynaecology and andrology. Current issues in endocrine surgery.
Improving the system of higher professional (medical) education,
information technologies for continuing professional education in
endocrinology, and many more.
According to long-standing tradition, the Congress was accompanied by
an exhibition that ran parallel to it and had in attendance some of the
leading manufacturers of pharmaceuticals and medical products companies,
both Russian and foreign.
GEROPHARM, being one of the experts in fully-localised, full-cycle
production of genetically engineered human insulin, also had its display
there. An innovative highlight of the display was the robot that would
tell the visitors of the Congress about the company and its
achievements. GEROPHARM, Group of Companies is engaged in the
development and production of Russia-made innovative medicines for
treatment of socially significant diseases treatment as well as of
generics that are prioritised in terms of import substitution
In 2013, the town of Obolensk in the Moscow region saw the opening of
GEROPHARM-Bio, an industrial GMP complex. This enterprise is
unparalleled both in the Moscow region and Russia-wide as it creates an
environment for ensuring medicinal safety by localising, for the first
time, all the phases of production of genetically engineered human
insulins, which are socially significant medicines, within the territory
of the country, as well as addresses the problem of import
substitution, which is so crucial today.
GEROPHARM is implementing a number of projects under federal
special-purpose programmes of the Ministry of Industry and Trade and the
Ministry of Education and Science of the Russian Federation, including a
project for creating insulin analogues.
GEROPHARM’s participation in an event of such significance to the endocrinology community is very important, because it provides an opportunity to obtain advanced scientific knowledge and practical expertise, to exchange experiences, and to make a name for the Group.